UCSF Recruting Breast Cancer Patients For Herbal Therapy Study

October 27, 1998

Researchers at the University of California San Francisco are recruiting patients for the first study in the U.S. that will determine the feasibility of using Chinese herbal therapy to alleviate the side effects of chemotherapy in women with early stage breast cancer.

Developed in collaboration at UCSF with Western breast cancer investigators and practitioners as well as non-Western herbalists, this study aims to scientifically evaluate the benefits of a Chinese herbal formula that is widely used by herbalists for cancer patients receiving chemotherapy. In addition, the trial will assess any toxicities associated with the use of the formula in conjunction with chemotherapy.

After conferring with many herbalists around the world, studying past clinical trials of herbal therapies, and reading text books on the subject, UCSF researchers developed a formula consisting of a range of herbs that they hope will alleviate multiple side effects of chemotherapy. The formula contains 21 herbs and has received an Investigational New Drug (IND) license from the Food and Drug Administration which is necessary to conduct a clinical trial.

This novel trial is a crucial first step to integrating traditional Chinese medicine, where effective, into the standard of care for breast cancer patients, UCSF researchers said.

"Ultimately, we would like to develop a model in which we integrate the parts of herbal therapies that are safe and effective with those that we know are effective in standard conventional therapy, such as chemotherapy," said Debu Tripathy, MD, UCSF associate professor of medicine, director of clinical research at the UCSF Carol Franc Buck Breast Care Center and principal investigator of the study.

In the U.S., most women are diagnosed with breast cancer at an early stage. Chemotherapy is being recommended more often as studies now show a clear reduction in the risk of cancer spread, Tripathy said. However, he added that the treatment is often accompanied by side effects including fatigue, nausea, vomiting, lowered white blood cell counts, hair loss, psychological distress and a decrease in quality of life.

In the San Francisco Bay area alone, it is estimated that 64 percent of women with breast cancer use at least one type of complementary therapy to reduce the side effects of Western treatment or improve their quality of life. Tripathy said that, because so many of his patients use alternative therapies, he feels it is his duty and responsibility to learn more about such treatments by scientifically evaluating them in clinical trials.

He designed a study that will provide breast cancer patients access to herbal therapy who typically would not receive a prescription for this treatment from their oncologists.

However, in order for the trial to be effective, he said, participants will be randomized to receive either the herbal formula or a placebo so that researchers can discern which side effects, if any, are caused by the herbal therapy versus chemotherapy. In addition, this will enable researchers to get a better approximation of the herbal therapy's benefits in terms of a patient's lowered side effects.

It is a double-blind study, meaning that neither the patient nor the doctor will know who is receiving the herbal treatment or placebo. All participants will receive standard (non-herbal) supportive treatments for side effects of chemotherapy, including anti-nausea and pain medications. Women who are eligible for the study must be about to receive the commonly used regimen of Adriamycin and Cytoxan (AC) chemotherapy and have Stage I or Stage II breast cancer. Participants will begin taking the Chinese herbal formula two weeks before their first chemotherapy session. It comes in powder form, and is mixed with warm water to be taken like a tea. Each patient's progress will be followed closely over a 180-day period by a research team including a medical oncologist, epidemiologist, and licensed herbalist/acupuncturist. Patients will also complete questionnaires throughout the study regarding their overall health, sense of well being, and experience with the herbal formula. The study will run for approximately 12-18 months and involves 60 women. The Arkay Foundation, a non-profit organization interested in women's health and alternative therapies, helped to fund the clinical trial. It has been approved by UCSF's Cancer Center Scientific Protocol Review Committee and the Committee of Human Research.
For more information or to participate in the study, please call Erika Leemann at (415) 885-7328 or by email at erika_leeman@quickmail.ucsf.edu

University of California - San Francisco

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.